TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group

While the primary endpoint of the study was not met, we noticed a subgroup of patients with a markedly discrepant TTP with trabectedin in comparison to previous therapy (GMI <0.5 or >2, the latter including some patients with a long TTP with trabectedin). A mismatch between PFS and overall survival was observed, possibly due to the natural history of the two different histologies and the availability of further lines in LMS.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2024-08-01
DOI
https://doi.org/10.1016/j.esmoop.2024.103667
Citations
5
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
2.09
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group

Alfredo Berruti, Alessandro Mazzocca, Chiara Fabbroni, Angelo Paolo Dei Tos et al.
5 citations
ESMO Open
Sarcoma Diagnosis and Treatment
2.09
article

TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group

Alfredo Berruti, Alessandro Mazzocca, Chiara Fabbroni, Angelo Paolo Dei Tos, Andrea Marrari, Paolo G. Casali, Sonia Fatigoni, Maria Abbondanza Pantaleo, Monica Giordano, Annalisa Alberton, Antonella Boglione, Tommaso Martino De Pas, Giovanni Grignani, Eliana Rulli, Elena Fumagalli, Roberta Sanfilippo, Luciano Carlucci, Giacomo Giulio Baldi, Bruno Vincenzi, S. Aliberti, Antonella Brunello
article en
5 citations

Abstract

While the primary endpoint of the study was not met, we noticed a subgroup of patients with a markedly discrepant TTP with trabectedin in comparison to previous therapy (GMI <0.5 or >2, the latter including some patients with a long TTP with trabectedin). A mismatch between PFS and overall survival was observed, possibly due to the natural history of the two different histologies and the availability of further lines in LMS.

ESMO OpenVol. 9(8)
University of Padua (IT), Mario Negri Institute for Pharmacological Research (IT), Surgical Specialties (Canada) (CA), Istituto Oncologico Veneto (IT), Ospedale Humanitas Gradenigo (IT), Azienda USL di Bologna (IT), Azienda Ospedaliera S.Maria (IT), Humanitas Gavazzeni (IT), Azienda Socio Sanitaria Territoriale Lariana (IT), Campus Bio Medico University Hospital (IT), Candiolo Cancer Institute (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), IRCCS Humanitas Research Hospital (IT), Hospital of Prato (IT), European Institute of Oncology (IT), University of Brescia (IT)
Zero hunger
Openalex Percentile: Top 12%
Sarcoma Diagnosis and Treatment
2.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.